WOBURN, Mass., March 29 /PRNewswire/ -- SRU Biosystems, a leader in highly sensitive labeled and label-free detection technologies, today announced that it has secured an exclusive license to Evanescent Resonance (ER) technology, a detection platform that enhances the sensitivity of fluorescence-based assays for drug discovery and diagnostics. Novartis has granted SRU the exclusive rights to the ER technology for use in drug discovery, as well as all supporting intellectual property rights. The sensitivity of ER technology should make it possible to profile the entire genome utilizing minute samples, or to perform ultra-sensitive ELISAs.
“The addition of ER technology to our portfolio means that SRU has the most sensitive labeled and label-free detection technology at our fingertips,” commented Owen Dempsey, President and CEO of SRU Biosystems. “We are excited to bring the capabilities of both the ER platform and our label-free BIND(R) system together in ways never used before that may enhance companies’ drug discovery and diagnostics efforts. This technology works with virtually any luminescence-based label, while increasing assay sensitivity 100-fold. Additionally, this technology, which is incorporated into standard microarray slides and microtiter plates, is compatible with existing infrastructure and commercial equipment on the market, furthering its commercial attractiveness to researchers.”
The ER technology is a luminescence-based platform that utilizes an optical amplification to enhance signal intensities, which in one embodiment enables precise measurement of gene expression from very small samples that include less than one nanogram of RNA; traditional microarrays require much more RNA for gene expression profiling. Utilizing ER, the fluorophores attached to samples are excited more efficiently when compared to standard assays, resulting in up to a 100-fold increase in the level of fluorescence signals and corresponding improved detection limits.
About SRU Biosystems
SRU Biosystems, Inc., is a life science company developing novel technologies for rapidly analyzing the interactions of large genomic, protein, peptide, antibody or small molecule compound libraries against a wide range of biochemical targets. SRU is incorporating its technology into microtiter plates, microarray slides and other industry standard formats to create sensitive and high throughput tools that can be used to answer important biological questions for biomedical research, pharmaceutical drug discovery and diagnostics.
For more information, please contact: Brant Binder CFO, SRU Biosystems, Inc. Bbinder@srubiosystems.com +1 781-933-7255, ext. 202 Or Jennifer Greenleaf MacDougall Biomedical Communications +1 508-647-0209
SRU Biosystems
CONTACT: Brant Binder, CFO of SRU Biosystems, Inc., +1-781-933-7255, ext.202, Bbinder@srubiosystems.com; or Jennifer Greenleaf of MacDougallBiomedical Communications, +1-508-647-0209
Web site: http://www.srubiosystems.com/
